Sacubitril/valsartan, a combination of two cardiac drugs, was approved by the US FDA for the treatment of symptomatic heart failure with systolic dysfunction. Systolic dysfunction is when the heart is unable to contract with enough force, and is therefore unable to pump blood to the rest of the body efficiently. The availability of the sacubitril/valsartan combination and ivabradine for the treatment of heart failure has prompted three large cardiac organizations.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer